ELVN logo

Enliven Therapeutics (ELVN)

Profile

Full Name

Enliven Therapeutics, Inc.

Ticker Symbol

ELVN

Exchange

NASDAQ

Country

United States

IPO

March 12, 2020

Indexes

Not included

Employees

62

Key Details

Price

$16.07(-5.75%)

Market cap

$787.50M(Small cap)

Last Dividend

-

TTM Dividend yield

-

Annual revenue

-

Annual EPS

-$1.89(+5.97% YoY)

PE ratio

-

Next earnings date

May 14, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price Performance

Price Range

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Shares Outstanding

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

EPS

Profit

Expenses

EBIT & EBITDA

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Liabilities

Debt

Equity & Capital

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

CAPEX

Free Cash Flow

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

ROA & ROE

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Analyst ratings

Recent major analysts updates

Mar 21, 25 HC Wainwright & Co.
Buy
Dec 13, 24 BTIG
Buy
Nov 15, 24 Baird
Outperform
Oct 31, 24 Jones Trading
Buy
Oct 1, 24 HC Wainwright & Co.
Buy
Sep 9, 24 HC Wainwright & Co.
Buy
Jun 11, 24 Baird
Outperform
Apr 9, 24 Mizuho
Buy
Mar 29, 23 Jefferies
Buy
Mar 3, 23 TD Cowen
Outperform

Institutional Ownership

  • What is the ticker symbol for Enliven Therapeutics?
  • Does Enliven Therapeutics pay dividends?
  • What sector is Enliven Therapeutics in?
  • What industry is Enliven Therapeutics in?
  • What country is Enliven Therapeutics based in?
  • When did Enliven Therapeutics go public?
  • Is Enliven Therapeutics in the S&P 500?
  • Is Enliven Therapeutics in the NASDAQ 100?
  • Is Enliven Therapeutics in the Dow Jones?
  • When was Enliven Therapeutics's last earnings report?
  • When does Enliven Therapeutics report earnings?
  • Should I buy Enliven Therapeutics stock now?

What is the ticker symbol for Enliven Therapeutics?

The ticker symbol for Enliven Therapeutics is NASDAQ:ELVN

Does Enliven Therapeutics pay dividends?

No, Enliven Therapeutics does not pay dividends

What sector is Enliven Therapeutics in?

Enliven Therapeutics is in the Healthcare sector

What industry is Enliven Therapeutics in?

Enliven Therapeutics is in the Biotechnology industry

What country is Enliven Therapeutics based in?

Enliven Therapeutics is headquartered in United States

When did Enliven Therapeutics go public?

Enliven Therapeutics's initial public offering (IPO) was on March 12, 2020

Is Enliven Therapeutics in the S&P 500?

No, Enliven Therapeutics is not included in the S&P 500 index

Is Enliven Therapeutics in the NASDAQ 100?

No, Enliven Therapeutics is not included in the NASDAQ 100 index

Is Enliven Therapeutics in the Dow Jones?

No, Enliven Therapeutics is not included in the Dow Jones index

When was Enliven Therapeutics's last earnings report?

Enliven Therapeutics's most recent earnings report was on Mar 13, 2025

When does Enliven Therapeutics report earnings?

The next expected earnings date for Enliven Therapeutics is May 14, 2025

Should I buy Enliven Therapeutics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page